✨ Free AI Report
Vifor Pharma Ltd: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Vifor Pharma Ltd
Company Research

Vifor Pharma Ltd: Business Overview, Financials & Competitive Analysis

Vifor Pharma is now a subsidiary of CSL Limited following acquisition in August 2022. Operating as CSL Vifor, the company specializes in therapies for iron deficiency, nephrology, and cardio-renal diseases with a sign...

Analyst-debate audio for Vifor Pharma Ltd

AskCyborg analysts argue the bull and bear cases for Vifor Pharma Ltd across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Vifor Pharma Ltd Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Vifor Pharma Ltd Overview

Pro stress-test →

Vifor Pharma is now a subsidiary of CSL Limited following acquisition in August 2022. Operating as CSL Vifor, the company specializes in therapies for iron deficiency, nephrology, and cardio-renal diseases with a significant portfolio in chronic kidney disease management and anemia treatment.

Strategic Profile

Pro stress-test →

Vifor Pharma operated as a specialty pharmaceutical company leveraging a joint venture with Fresenius Medical Care for nephrology products. The business focused on high-unmet-need therapeutic areas supported by in-licensing and strategic partnerships.

Competitive Landscape

Pro stress-test →

As a CSL subsidiary, Vifor Pharma competes in nephrology, iron deficiency, and cardio-renal therapeutic areas. Prior to acquisition, key competitors included other specialty pharma companies and dialysis providers serving chronic kidney disease and anemia markets.

Industry Context

Vifor Pharma Ltd operates in Pharmaceuticals.

Key facts

Founded: 2008 · Headquarters: Glattbrugg, Zurich, Switzerland · Employees: Approximately 2,600 at acquisition · Revenue: Estimated $1B+ at time of acquisition (2022) · Market cap: N/A (Acquired subsidiary)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Vifor Pharma Ltd.

  • Iron franchise (Ferinject/Injectafer) generated strong growth; patent exclusivity in US extended through July 2026 at time of last public disclosure.
  • Nephrology market estimated at over $25 billion by 2026 with aging population driving chronic kidney disease prevalence and treatment demand.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • August 2022Acquisition by CSL Limited completed for USD $179.25 per share (USD $11.7B equity value)
  • December 2021CSL Limited announced definitive agreement to acquire Vifor Pharma
  • +1 moreTrack every material event for Vifor Pharma Ltd as it happens. Explore monitoring →
Get alerted when Vifor Pharma Ltd has a new material development →

Compare Vifor Pharma Ltd with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Vifor Pharma Ltd operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Vifor Pharma Ltd

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Vifor Pharma Ltd and its top competitor on Cyborg Score”
“What did Vifor Pharma Ltd do this quarter?”
“Is Vifor Pharma Ltd a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Vifor Pharma Ltd do?+
Vifor Pharma is now a subsidiary of CSL Limited following acquisition in August 2022. Operating as CSL Vifor, the company specializes in therapies for iron deficiency, nephrology, and cardio-renal diseases with a sign...
What is Vifor Pharma Ltd's Cyborg Score?+
The Cyborg Score is a 1-10 rating from the AskCyborg multi-agent analyst-debate framework. Recalibrated weekly across business, financials, leadership, competitive position, technology, marketing, and ESG dimensions.
Who are Vifor Pharma Ltd's main competitors?+
The full competitive landscape for Vifor Pharma Ltd is in the AskCyborg report.
How can I get the full Vifor Pharma Ltd research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Vifor Pharma Ltd research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.